Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Suzhou Xinkanghe Biomedical Technology

Request full access

First-in-class antibody therapies for cancer and autoimmune diseases

ChinaFounded 2015

About Suzhou Xinkanghe Biomedical Technology

Suzhou Xinkanghe Biomedical Technology (Kanovabiopharma) is a biopharmaceutical company established in November 2015 with its headquarters in BioBAY, Suzhou. The company focuses on the research and development of innovative antibody drugs for oncology and inflammatory diseases. Kanovabiopharma was founded by a world-renowned immunologist and aims to develop first-in-class therapeutic antibodies and novel combination therapies.

The company's scientific advisory board is led by Professor Chen Dong, a prominent immunologist recognized for his discovery of Th17 cells and their role in immune diseases. The leadership team includes CEO Yaning Wang, who has 30 years of experience in pharmaceutical companies, and SVP Dr. Li Guo, who has 20 years of experience in novel biologics discovery.

Kanovabiopharma's pipeline includes several antibody drug candidates. Its IL-17A/F antibody has reached the primary endpoint in a Phase III clinical trial for ankylosing spondylitis. Another key drug, XKH001, received FDA approval for clinical trials. The company's business model revolves around in-house research and development, strategic collaborations, and out-licensing of its assets, such as the XKH004 program. It operates in the global biopharmaceutical market, addressing unmet medical needs in immunology. The company has successfully raised capital through multiple financing rounds, including Pre-A, A, B, and B+ rounds to fund its research and clinical programs.

Source: Dealroom company data

At a glance

Status
Operational
Employees
4
Open positions
None listed
Dealroom signal
18.3/100

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Jul 2023 $14M $55M ShenZhen GTJA Investment Group ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Suzhou Xinkanghe Biomedical Technology website traffic

Latest recorded traffic for Suzhou Xinkanghe Biomedical Technology is 440 monthly website visits, down 38.9% over the last three months. Suzhou Xinkanghe Biomedical Technology's team grew 0% over the past year.

Latest monthly visits440 3-month web change-38.9% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Suzhou Xinkanghe Biomedical Technology in its local ecosystem

Live from Dealroom

The Suzhou Xinkanghe Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • ShenZhen GTJA Investment Group

Other known investors2 additional known investors

  • 3H Health Investment
  • CD Capital
Employees 4 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Suzhou Xinkanghe Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Suzhou Xinkanghe Biomedical Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.